Clinical Trial Search

Primary: Percentage of Participants Who Are Headache Pain Free In High Dose Group (200 mg Lasmiditan) — 16.6; 40.8 percentage of participants — p=<0.001

Primary: Pain Intensity on Movement — 3.4; 2.7; 3.9 score on a scale — p=0.0031

Primary: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score — 39.8; -1.3; -2.5; -5.0 units on scale

Primary: Ratio of UACR at Day 90 to UACR at Baseline — 0.869; 0.89; 0.824; 0.739 Ratio — p=0.1973

Primary: Number of Patients Completing Week 12 of Treatment — 9; 10; 0; 7 Participants

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) — -62.34; -69.21; -72.09; -41.12 percent change — p=0.0165

Primary: Mean Change From Baseline at Week 16 in the Mean Worst Daily Itch Score — -1.73; -2.19; -2.60; -2.60 Scores on a scale

Primary: Change From Baseline in mRSS at Week 4 — -2.2; -1.6 units on a scale — p=0.6757

Primary: Number of Participants With Cessation Success at Week 10 After Target Quit Date — 12; 7 Participants with cessation success

Primary: Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period — 19.35; 49.01 hot flushes — p=<0.0001

Primary: Change From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12 — -1.12; -2.56; -1.52; -1.32 units on a scale — p=<0.001

Primary: Number of Participants With Complete Remission (CR) — 68 Participants

Primary: Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 8 Ante Meridiem (AM) (0 Hour) — 22.77; 22.41; 5.00; 3.79 mmHg

Primary: Number of Patients Achieving Pathologic Complete Response (pCR). — 25; 9; 90; 56 Participants

Primary: Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I — 25.97; 26.25; 25.90; 26.44 mmHg — p=0.028